Henry Meds Semaglutide Review: Flat-Rate Pricing and 2026 Status

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the compounded semaglutide provider comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Rachel, a 41-year-old marketing manager in Charlotte, spent three weeks in January 2026 spreadsheet-comparing telehealth GLP-1 providers. She'd been burned before. "I signed up for a $99 introductory rate with another company," she told us. "Month two was $249. Month four was $349. By month six I was paying more than branded Ozempic through my old insurance plan." She switched to Henry Meds in February, and her bill has been $297 every month since, including when her dose climbed from 0.5 mg to 1.7 mg. "It's boring. Boring is what I wanted."

That story captures the entire Henry Meds pitch: boring, predictable pricing in a market that has trained patients to expect bait-and-switch. Whether that pitch holds up under scrutiny in 2026, and whether "boring" is enough, is what this review is about.

This review sits inside the broader best compounded semaglutide telehealth providers comparison, which is part of the compounded semaglutide pillar guide.

What You Actually Get for $297 a Month

Henry Meds offers compounded semaglutide on a month-to-month basis at $297 flat, regardless of dose tier. That price covers the medication, shipping, and access to clinical support through the platform. No annual commitment. No introductory discount that quietly expires. The price a patient pays in month one is the same price at the highest dose.

The medication is compounded by 503A pharmacy partners under individual prescriptions. The 2026 formulation, consistent with how post-shortage compounding works across the industry, is typically semaglutide combined with a personalization additive such as B12. This keeps the prescription inside the 503A clinical-need exception that survived the FDA's February 2025 shortage resolution.

The clinical model is asynchronous-first. Your initial consultation is a structured questionnaire reviewed by a licensed clinician in your state.

Why Flat-Rate Pricing Matters More Than It Sounds

Pricing structure in compounded GLP-1 telehealth is like gym memberships: the advertised rate and the actual cost over six months are often two different numbers.

Here's the thing about Henry Meds. A patient titrating from 0.25 mg to 2.4 mg over six months pays $1,782 total. That's it. No dose-escalation surcharge, no surprise "pharmacy fee" at month four.

The trade-off is obvious: that $297 first-month price looks expensive next to a competitor advertising $99. But you're comparing the steady-state price to a promotional rate. The comparison only holds for one month. By month three or four, many of those $99 providers have caught up to or passed $297.

There's no annual prepayment requirement, which means a patient who decides at month two that the side effects aren't manageable, or that the program isn't right, walks away clean. That flexibility has real dollar value, even if it doesn't show up in a price-comparison chart.

My take: in a market where pricing opacity has become the norm, Henry Meds's approach is one of its strongest differentiators. It's not the cheapest option, but it might be the most honest one.

Pharmacy Sourcing and Legal Standing

Henry Meds uses 503A pharmacy partners. The provider has historically disclosed its pharmacy partners on request after enrollment, though the pharmacy name doesn't appear on the public-facing website. This is standard practice in the category, not a red flag.

Two things worth knowing about Henry Meds's regulatory position in 2026:

First, the company has not been named as a defendant in the active Novo Nordisk civil litigation against compounding-chain participants alleging "inauthentic API" sourcing. Based on a review of public court records in early 2026, that litigation has primarily targeted upstream compounders and smaller distributors rather than the larger consumer-facing telehealth brands.

Second, Henry Meds has not been the subject of an FDA warning letter. That's a meaningful distinction in 2026, when several peers have faced regulatory action on marketing claims. Clean is not the same as perfect, but clean is better than not.

The Clinical Experience (And Its Limits)

The clinical model is asynchronous. You fill out a questionnaire. A licensed clinician reviews it. You communicate with the clinical team through the platform. Clinical messaging doesn't generate an additional fee, and Henry Meds publishes a response-time standard.

The provider operates with a named medical director, visible on the company's regulatory and provider-network disclosures.

Here's where this falls apart for some patients: baseline lab requirements are not universal. Henry Meds recommends labs but doesn't always gate initiation on them. That's a clinical call, not necessarily a wrong one, but patients should seriously consider obtaining baseline TSH, A1C, and basic metabolic markers before starting therapy. Do it through Henry Meds's lab partnership or through your primary care physician. Don't skip this step just because the platform lets you.

Dose escalation follows a standard schedule unless the clinician adjusts. Patients can request dose holds or step-downs through the platform.

The patients who thrive on Henry Meds are the ones who want a transparent, predictable cost structure and are comfortable communicating with clinicians through a platform rather than a phone call. Patients who want a clinician-led, high-touch relationship (think scheduled video visits, proactive check-ins, a provider who knows your name without looking it up) are usually better served by a clinician-network model like Mochi Health or a clinician-led practice like Lavender Sky Health.

LegitScript Certification and State Coverage

Henry Meds is LegitScript-certified, verifiable on the LegitScript registry. This is one of the more reliable third-party trust signals in the telehealth space, and not every competitor has it.

State coverage is broad, roughly 48 states. The excluded states shift periodically based on state-specific telehealth regulations, so confirm availability in your state before starting the onboarding process.

The 2026 Regulatory Picture

The FDA's February 2025 declaration that the semaglutide shortage was resolved changed the rules for every provider in this space. Under section 503A of the Federal Food, Drug, and Cosmetic Act, 503A pharmacies may still compound semaglutide for an individual patient when there is a documented clinical reason that the commercial product doesn't meet that patient's needs. The large-scale 503B production that was permitted during the shortage is no longer available.

Henry Meds transitioned, like most peers, to a personalization formulation satisfying the patient-specific clinical-need standard. The provider has not faced FDA enforcement actions on the transition, which distinguishes it from Hims and a small number of other providers that have received warning letters on marketing claims related to compounded GLP-1 preparations.

Think of the current regulatory environment like driving 5 mph over the speed limit on a highway: most people are doing it, some are doing 15 over, and the ones getting pulled over are the ones weaving between lanes. Henry Meds is, by all available public evidence, staying in its lane.

Henry Meds vs. HealthRX

For patients comparing these two, the structural similarities are considerable. Both are flat-rate pricing models with no annual commitment. Both use 503A pharmacy partners and disclose on request. HealthRX is LegitScript-certified. Both operate asynchronous-first clinical models with published response-time standards.

The pricing differences are real but modest. Henry Meds is $297 flat. HealthRX runs $179.99 to $279.99 flat-rate, with the lower price points tied to specific plans. A patient choosing between the two on price alone will save with HealthRX. A patient choosing on brand recognition or longer operating history may lean toward Henry Meds.

Most patients who have tried both report that the structural similarities outweigh the differences. The choice often comes down to which platform's onboarding process feels more comfortable, which is a perfectly valid way to make the decision.

Henry Meds vs. Hims

These two anchor opposite ends of the asynchronous-first market on pricing philosophy. Henry Meds: $297 flat, no commitment. Hims: $199 with annual commitment or $299 monthly with dose-tier escalation.

The math depends on how long you plan to stay:

A patient who stays the full twelve months pays roughly $2,388 with Hims's annual rate and $3,564 with Henry Meds. A patient who stays four months pays $796 with Hims's annual rate (if locked in, the unused months still count) or $1,188 with Henry Meds (with the option to cancel at any time, no penalty).

The structural difference matters most for patients who aren't sure about duration. If you're testing the waters, Henry Meds's no-commitment structure is friendlier. If you're confident you'll use the program for a full year, Hims's annual rate saves you roughly $1,176.

The regulatory comparison matters too. Hims received an FDA warning letter on marketing claims in September 2025. Henry Meds has not been the subject of an FDA enforcement action. Both providers continue to operate. Neither status disqualifies the provider, but it's a public-record data point.

These are worth asking during or right after the consultation:

Which 503A pharmacy will fill my prescription, and in which state is it licensed?
What is the exact formulation of the compounded preparation, and what additive is used?
If I have a clinical question, what is the response-time standard?
Are baseline labs included in the program, or do I need to obtain them externally?
What is the protocol for dose holds, step-downs, or pause-and-resume?
What happens at month twelve if I want to continue on a maintenance dose?

Frequently Asked Questions

Is Henry Meds legitimate? Yes. Henry Meds is LegitScript-certified, uses licensed 503A pharmacy partners, and has not been the subject of FDA enforcement actions or named in the Novo Nordisk compounding litigation as of early 2026.

How much does Henry Meds semaglutide cost? $297 per month, flat-rate across all dose tiers. No annual commitment, no introductory rate that resets higher.

Does Henry Meds require labs before starting? Labs are recommended but not universally required for initiation. Patients should strongly consider getting baseline TSH, A1C, and basic metabolic markers before starting.

Can I cancel Henry Meds at any time? Yes. The program is month-to-month with no annual lock-in.

How does Henry Meds compare to branded Ozempic or Wegovy? Henry Meds provides compounded semaglutide, which is not the same as the branded products. Compounded semaglutide is not FDA-approved. The clinical evidence supporting semaglutide (STEP-1, Wilding et al., NEJM 2021; STEP-3, Wadden et al., JAMA 2021; STEP-4, Rubino et al., JAMA 2021; SELECT, Lincoff et al., NEJM 2023) was generated using the branded formulations.

Is Henry Meds available in my state? Coverage spans roughly 48 states. Confirm availability during onboarding, as excluded states change based on evolving telehealth regulations.

Does Henry Meds accept insurance? No. The program is cash-pay only. The $297 monthly fee covers the medication, shipping, and clinical access.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies under individual prescriptions for clinically documented patient-specific need. Pricing and program terms for Henry Meds are based on public information available in early 2026 and are subject to change. References: SUSTAIN program; STEP-1 (Wilding et al., NEJM 2021); STEP-3 (Wadden et al., JAMA 2021); STEP-4 (Rubino et al., JAMA 2021); SELECT (Lincoff et al., NEJM 2023); FDA Drug Shortage status update, February 2025.